National Cancer Institute – NCI shared on LinkedIn:
“ ‘NCI is committed to advancing pediatric brain cancer research, and that commitment requires a clinical trials program that is scientifically strong, effective, and responsive to the needs of children with cancer and their families. We know how urgently families need better treatments, and we have a responsibility to ensure our clinical trials program gives promising science the best opportunity to reach patients.
In late 2024, NCI leadership began a review to determine which network of research sites would be the best future partner for conducting early-phase clinical trials for children with brain tumors.
In July, NCI decided to move primary responsibility for these trials from the 16-site Pediatric Brain Tumor Consortium (PBTC) to the larger Pediatric Early Phase Clinical Trials Network (PEP-CTN).
PEP-CTN is a network of 42 sites with the infrastructure to develop and open trials and enroll patients at the pace needed for children with brain tumors.
The decision focused on how best to support the research field and serve children and families. Children who were receiving treatment through PBTC studies were able to continue their protocol-specified treatment.
The transition to PEP-CTN was not undertaken as a cost-cutting measure; the $4 million previously allocated to PBTC will support PEP-CTN research activities, including a major expansion of its brain tumor research portfolio.
Additionally, the new PEP-CTN structure provides opportunities to draw on the significant expertise of pediatric neuro-oncologists who participated in PBTC while also engaging additional investigators, including members of the Children’s Oncology Group Central Nervous System Tumor Committee.

I am deeply grateful for the contributions of PBTC and for the children and families who made this important research possible. Science evolves, and research infrastructure must evolve with it. The work on PEP-CTN will build upon the solid foundation of PBTC.
As NCI Director, I am personally committed to ensuring the success of this program. That means closely evaluating how quickly trials open and whether they enroll patients effectively, and continuing to engage investigators, advocates, and families as we move forward.
Our responsibility is to ensure that children with brain tumors have the best possible opportunities to benefit from advances in research. That commitment will continue to guide NCI’s work.’
– Tony.”
You can also read: